ArticleProstate cancer and prostatic diseases2023
Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study.
Article in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Sexual Function and Clinical Outcomes Following Rezūm Therapy for Benign Prostatic Hyperplasia: An Updated Systematic Review Including Large Prostate Volumes.Lower urinary tract symptoms · 2026Pooled it
- Management of NOACs in patients undergoing water vapour thermal therapy (REZUM) for benign prostatic obstruction: a comprehensive review.World journal of urology · 2025Pooled it
- Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement.World journal of urology · 2025Pooled it
- Short term results after minimally invasive treatments for benign prostatic enlargement: the first randomized trial comparing transperineal laser ablation and water vapor ablation.Prostate cancer and prostatic diseases · 2025Trial
- How does PSA change after water vapor therapy? A systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Review
- Thulium laser incision of prostate with selective median lobe vaporesection versus water vapor thermal therapy in the treatment of benign prostatic obstruction with ejaculation-sparing intent: a retrospective, comparative analysis from two institutions.International urology and nephrology · 2026Article
- Water vapor thermotherapy and high-grade Clavien-Dindo complications: retrospective analysis of 10 cases.World journal of urology · 2026Article
- The impact of minimally invasive surgical therapy for Benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Review
- The dark side of transurethral access for LUTS/BPH surgery: a narrative review.Asian journal of andrology · 2026Review
- Rezūm water vapor therapy vs. thulium laser enucleation for the treatment of benign prostatic hyperplasia in patients with large prostates: a multicenter prospective comparative study.Prostate cancer and prostatic diseases · 2025Article
- Safety and efficacy of WVTT (Rezum) in young men: preliminary data.International urology and nephrology · 2025Article
- Real-world experience of water vapour therapy (Rezum) in patients with benign prostatic enlargement: a retrospective single-center study.Prostate cancer and prostatic diseases · 2025Article
- Trans - Perineal laser ablation of the prostate in high surgical risk patients affected by severe lower urinary tract symptoms related to benign prostatic obstruction.Prostate cancer and prostatic diseases · 2024Article
- Transperineal laser ablation (TPLA) of the prostate for benign prostatic obstruction: the first 100 patients cohort of a prospective, single-center study.World journal of urology · 2024Article
- Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation.Prostate cancer and prostatic diseases · 2024Review
- The influence of preoperative urodynamic parameters on clinical results in patients with benign prostatic hyperplasia after transurethral resection of the prostate.World journal of urology · 2024Article
- Thulium laser transurethral incision of the prostate with ejaculation-sparing intent: 2-year follow-up outcomes from a high-volume centre.Central European journal of urology · 2024Article
- Prospective Trial of Water Vapor Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia in Subjects with a Large Prostate: 6- and 12-month Outcomes.European urology open science · 2023Article
- Ejaculation physiology and dysfunction after BPH surgery: the role of the new MISTs.Prostate cancer and prostatic diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Rezum system is one of the latest minimally invasive surgical treatments for benign prostatic hyperplasia.
methodsWe retrospectively reviewed all patients who underwent the Rezum treatment in seven different Italian institutions. A successful urinary outcome was defined as: ≥50% improvement in the IPSS <7, improvement in peak flow ≥50% and/or more than 15 ml/s, ≥1-point improvement in the QoL questionnaire and in the absence of perioperative major complications (AUR, transfusion) or postoperative incontinence. A successful sexual outcome was defined as postoperative (latest follow up consultation) antegrade ejaculation or no variation in ejaculatory function and an increase, or stability or max 1 class reduction, in IIEF-5.
results262 patients were enrolled with a follow-up period of 11 months (IQR 5-15). No early or late serious adverse events (Clavien III-IV) occurred. Early complications occurred in 39.3% of cases, with 4 cases of clot retention and one case of blood transfusion. Urge incontinence was reported by 6 patients (2.2%). A treatment failure requiring re-intervention occurred in 4 cases (1.5%). The preoperative antegrade ejaculation rate was 56.5%, and after the procedure it increased to 78.2%. The increase of ≥1-point in the QoL was achieved in 92.7% of the cases. Optimal urinary and sexual outcomes were achieved in 52.9% and 87.8%, respectively.
conclusionsIn our series, water vapor intraprostatic injections seem to be an effective and safe procedure.
Indexed as
Identifiers
36042295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.